Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDK12 del |
Therapy | Veliparib |
Indication/Tumor Type | prostate cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDK12 del | prostate cancer | sensitive | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of a prostate cancer cell line with biallelic CDK12 truncations in culture (PMID: 39321214). | 39321214 |
PubMed Id | Reference Title | Details |
---|---|---|
(39321214) | Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. | Full reference... |